The Canadian government has authorized a startup to export psychedelic substances to Australia for medicinal purposes. Optimi Health Corp has been given the responsibility of transporting pills infused with psilocybin, an extract from magic mushrooms, and MDMA, as approved by the health department.
The growing demand is not limited to the domestic magic mushrooms Ontario. Other countries are following Canada’s lead and are beginning to investigate and allow the use of serotogenic compounds for medical treatments.
Rest assured, you can buy psychedelics online in Canada and unlock your inherent potential through trustworthy sources.
[toc]Main Highlights:
- Optimi Health, a Vancouver-based startup, has been given a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions spanning five to eight weeks, with each session lasting about eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a small Vancouver-based firm, aims to utilize its certification to broaden the pharmaceutical market for psychedelic drugs and establish an early market presence.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical trial purposes. An official from Canada’s health department could not confirm whether these exports were for regular patient use and chose not to reveal the companies for security reasons.
This accomplishment places Optimi among a limited group of worldwide suppliers, with the current market favoring clinical over recreational use.
What’s in the Pill?
While the company has not disclosed the specific type of mushroom used in the pill, they do work with a range of strains such as Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, examine, and extract its psychedelic mushrooms. This quaint town, home to approximately 3,000 inhabitants, is situated three hours to the east of Vancouver.
Australia’s Engagement with Psychedelic Mushrooms
Approximately 20% of Australians aged between 16 and 85 are likely to experience a mental health condition. Post-traumatic stress disorder (PTSD) might affect 11% of Australians during their lifetime, and 17% of the population suffer from anxiety disorders.
A variety of methods exist for treating mental health conditions, but not all are equally effective for every patient. Those who don’t respond to certain treatments may struggle to find a method that works for them, thus exacerbating their vulnerability.
Understanding the Process
Australia has been a frontrunner in using psilocybin, permitting licensed psychiatrists to apply this controlled substance in treating PTSD and treatment-resistant depression.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psilocybin mushrooms for therapeutic use. The TGA affirmed these substances are safe when used in a medically regulated environment for patients grappling with severe mental disorders.
This shift has proven to be revolutionary for numerous mental health specialists and researchers. The utilization of these substances will be strictly monitored; it isn’t as simple as taking a pill and leaving.
The treatment regimen typically consists of three sessions spanning five to eight weeks. Each of these sessions lasts approximately eight hours, with the therapist accompanying the patient throughout.
Canada’s Role in Psilocybin Research
Canada has surfaced as a key player in psilocybin research, significantly broadening our understanding of this substance. Health Canada, in collaboration with several institutions, is leading the way in investigating psilocybin’s therapeutic potential for various mental health disorders.
Research institutions are no longer forced to label these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to grow mushrooms for research purposes.
The increased access to substances previously deemed harmful allows researchers to extend their understanding of the potential benefits these substances could offer many individuals.
A Recurrent Trend
The potential of this area was initially identified in the 1950s as a means to tackle mental health disorders and substance dependency, including alcohol addiction. English psychiatrist, Humphry Osmond, and Canadian biochemist, Abram Hoffer, were pioneers of this pioneering research at the Weyburn The Saskatchewan Mental Hospital. This institution saw significant progress under the leadership of then-premier Tommy Douglas, who gave the medical community extensive freedom to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer embarked on investigations with LSD, mescaline, and peyote as potential alternatives to the harsh procedures of electroshock therapy and lobotomy. Their research took unexpected turns, leading to them advocating for medical staff, including doctors, nurses, and auxiliary personnel, to try these substances.
Canadian Health Research Institutes
Through the Institute of Neurosciences, Mental Health, and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in end-of-life patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a more thorough exploration of the benefits of regulated substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, has made this funding possible.
Further Psychedelic Research
Psychiatrists in Vancouver have started a phase III clinical trial of MDMA, also known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, scheduled one month apart, and nine 90-minute sessions without the drug. Researchers consider this trial to be of historical importance as it is the first clinical evaluation of an illicit substance.
This is the first psychedelic substance studied in over four decades.
A Closer Look at Psilocybin
Psilocybin, a naturally found psychedelic compound in certain mushroom species, metabolizes into psilocin once ingested. This resultant psilocin activates the serotonin 5-HT2a receptors situated on the brain’s cortical pyramidal cells, which are essential processing centers.
Local authorities are investigating the substance’s potential to aid in managing depression, anxiety, addiction, and end-of-life distress. This is accomplished by promoting introspection and spiritual enlightenment.
Why is Psilocybin Effective in Treating Depression, PTSD, and Other Conditions?
The active ingredient targets multiple brain areas, making it applicable for various mental disorders. Many patients in Canada and Australia have already undergone this therapy. The results have been promising, with minor side effects such as temporary anxiety or slightly increased blood pressure.
The Impact on Neurobiology
- Serotonin Receptor Activation: The substance partially acts as an agonist at serotonin receptors. It specifically targets the 5-HT2A subtype, which plays a key role in emotional processing and mood regulation.
- Default Mode Network (DMN) Modulation: The substance reduces DMN activity, stimulating introspection, minimizing rigid thought patterns, and promoting emotional adaptability.
- Activation of Prefrontal and Limbic Regions: The substance’s antidepressant effects are due to its influence on the brain’s prefrontal and limbic regions, including the amygdala. In depressive states, individuals often show a decreased response to emotional stimuli. The substance increases the response to positive emotional stimuli in the right amygdala and normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Consequences:
- Induction of Positive Mood States: The substance promotes feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience can help individuals to safely face and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that it may result in persistent positive changes, including boosted well-being, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Shops?
Wondering how the substance could affect your mental health? Browse through magic mushroom stores to discover a product that suits your needs.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, triggers creative thinking, and increases productivity and concentration |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Encourages improved health and enhances overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Contains a powerful mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Worldwide Acknowledgment of Psilocybin
Canada isn’t the only nation supporting the use of magic mushrooms for mental health challenges. Countries like Australia are also endorsing the use of these hallucinogens to treat conditions like depression and PTSD. They procure top-notch psychedelic capsules from trustworthy countries. With proper supervision, patients can significantly improve their life quality. Magic Mushrooms Hamilton Canada, a magic mushroom supplier, offers a variety of products, from tablets to LSD edibles.
Frequently Asked Questions
How are psilocybin and MDMA similar?
Both psilocybin and MDMA hold therapeutic potential for enhancing mental well-being. Psilocybin interacts with serotonin 2A receptors and is effective for treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD therapy. It demonstrates potential in improving emotional processing and despite its classification as a controlled substance.
Is this treatment option accessible to all Australians?
No. In Australia, a preliminary evaluation is required to ascertain an individual’s eligibility for using the substance. This assessment takes into account factors such as existing heart conditions, and a history of psychosis, among others. Only those patients who have not benefited from conventional treatments for conditions like depression, anxiety, or PTSD can avail of this treatment.
What is the impact of Canada exporting mushrooms?
By exporting mushrooms, Canada is establishing itself as a key player in the psychedelics market, mirroring its position in the cannabis industry. This could encourage more companies to produce high-quality products. As a result, Canada could lead the hallucinogen market, stimulate its economy, and ease the availability of these treatments for other countries. It may also discourage other countries from procuring their hallucinogens from illegal sources, thereby enhancing safety.
Articles That Might Interest You:
